<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology and pathogenesis of amyotrophic lateral sclerosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology and pathogenesis of amyotrophic lateral sclerosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology and pathogenesis of amyotrophic lateral sclerosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nicholas J Maragakis, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nestor Galvez-Jimenez, MD, MSc, MHSA, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 02, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amyotrophic lateral sclerosis (ALS), first described by Charcot in the 19
         <sup>
          th
         </sup>
         century [
         <a href="#rid1">
          1
         </a>
         ], is a relentlessly progressive, presently incurable neurodegenerative disorder that causes muscle weakness, disability, and eventually death. ALS is also known by the eponym "Lou Gehrig's disease," after the famous baseball player who was affected with the disorder. "Motor neuron disease" (MND) is the preferred term in the United Kingdom, but in the United States ALS and MND are sometimes used interchangeably.
        </p>
        <p>
         The epidemiology and pathogenesis of ALS are discussed in this topic review. Other aspects of ALS are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5138.html" rel="external">
          "Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5128.html" rel="external">
          "Disease-modifying treatment of amyotrophic lateral sclerosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5129.html" rel="external">
          "Symptom-based management of amyotrophic lateral sclerosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         ALS is classified as either sporadic or familial:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sporadic forms account for 90 to 95 percent of ALS cases.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Familial forms make up 5 to 10 percent of cases. (See
         <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">
          "Familial amyotrophic lateral sclerosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Incidence and prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Incidence rates for ALS in Europe and North America range between 1.5 and 4.7 per 100,000 person-years, while prevalence rates range between 2.7 and 7.4 per 100,000 person-years [
         <a href="#rid2">
          2-7
         </a>
         ]. In the United States, rates of ALS are higher among White individuals compared with those from other racial/ethnic groups [
         <a href="#rid5">
          5,6,8
         </a>
         ]. Similarly, a systematic review of global epidemiologic data concluded that the incidence of ALS may be higher among White individuals than in other populations [
         <a href="#rid9">
          9
         </a>
         ]. However, firm conclusions were precluded by the methodologic variation among studies.
        </p>
        <p>
         The male-to-female ratio is approximately 1.3 to 1.5 for sporadic ALS, although the ratio becomes closer to unity in the age group over 70 years. The incidence of ALS increases with each decade, especially after age 40 years, and it peaks at age 74, decreasing thereafter [
         <a href="#rid2">
          2,6
         </a>
         ]. In a systematic review, the peak incidence of ALS onset fell between 60 and 75 years in the majority of studies [
         <a href="#rid10">
          10
         </a>
         ]. In the United States, approximately 7000 new cases of ALS are diagnosed each year.
        </p>
        <p>
         The incidence and mortality rates of ALS have been slowly increasing over decades [
         <a href="#rid11">
          11-13
         </a>
         ]. Part or all of this increase in ALS incidence may be due to longer life expectancy [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The only well-established risk factors for ALS are age and family history. Accumulating evidence suggests that cigarette smoking is also a risk factor for ALS [
         <a href="#rid15">
          15-19
         </a>
         ]. The role of genetic variation in the pathogenesis of sporadic ALS is reviewed below. (See
         <a class="local">
          'Genetic susceptibility in sporadic ALS'
         </a>
         below.)
        </p>
        <p>
         There are weaker or conflicting data for other putative risk factors, a list that includes military service, agricultural work, factory work, heavy manual labor, exposure to pesticides, exposure to welding or soldering, exposure to heavy metal, work in the plastics industry, repetitive muscle use, athleticism, playing professional football or soccer, trauma, electrical shock, low-frequency magnetic fields, early-onset alopecia, decreased premorbid body fat, and a diagnosis of polymyositis [
         <a href="#rid20">
          20-42
         </a>
         ].
        </p>
        <p>
         Paradoxically, other data suggest that mortality from ALS is increased among people with higher socioeconomic occupations (eg, education, computers and mathematics, law, and architecture and engineering) where exposure to toxins is unlikely, while ALS mortality is decreased among people with lower socioeconomic occupations (eg, mining and drilling, construction, farming, fishing, and forestry) where exposure to toxins is more likely [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Some studies suggest potential links between alterations of the gut microbiome and ALS that could provide opportunities for therapeutic intervention [
         <a href="#rid44">
          44,45
         </a>
         ].
        </p>
        <p>
         Despite reports of exposure to mercury, lead, and aluminum in ALS cases [
         <a href="#rid21">
          21,26
         </a>
         ], the role of heavy metal exposure in the etiology of ALS remains controversial [
         <a href="#rid27">
          27-29
         </a>
         ]. No convincing case of lead toxicity mimicking ALS has been reported in several decades [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         The possible role of environmental exposure as an ALS trigger is supported by the finding that the incidence of ALS in young United States Gulf War veterans is approximately twofold higher than expected [
         <a href="#rid31">
          31,32
         </a>
         ]. The risk ratio for developing ALS was statistically significant in Army and Air Force veterans, while a trend toward increased risk for veterans of the Reserves, National Guard, Marines, and Navy did not reach statistical significance, possibly because of the relatively small number of subjects in those branches. Despite the higher incidence among Gulf War veterans, no common link was identified among potential exposures or activities in veterans who developed ALS. Because ALS is a relatively rare disease, the strength of these findings is reduced by the small number of cases and potential methodologic flaws [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         A subsequent, large cohort study of males (median age 57 years at cohort entry in 1982) found that United States military veterans had an increased death rate from ALS compared with non-veterans (adjusted relative risk 1.58, 95% CI 1.14-2.19) [
         <a href="#rid33">
          33
         </a>
         ]. As with previous studies, this higher incidence seemed independent of the branch of the military in which subjects served, except for the Marines, a subgroup with a small number of subjects. The increased risk of death from ALS was similar in veterans who served in the military during World War II, Korea, or Vietnam. There was no association between risk for developing ALS and the number of years served in the military. This result argues against a specific environmental trigger related to the Gulf War being a cause of ALS, since the association with ALS in the larger cohort study was largely independent of the time period of military service.
        </p>
        <p>
         The potential risk factors that military personnel would share over the many decades of military service studied are numerous and include inhalation of aerosolized lead used in vehicle finishing operations, exposure to the pesticide DEET, traumatic injuries, viral infections, and intense physical activity. However, none of these are established as risk factors, and confirmation of these factors awaits further study.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Genetic susceptibility in sporadic ALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Variations in a number of genes and loci appear to be associated with ALS susceptibility [
         <a href="#rid47">
          47
         </a>
         ]. The list includes known or suspected familial ALS genes, such as pathogenic variants in the
         <em>
          SOD1
         </em>
         ,
         <em>
          TARDBP
         </em>
         ,
         <em>
          C9ORF72
         </em>
         ,
         <em>
          FUS
         </em>
         ,
         <em>
          ANG
         </em>
         ,
         <em>
          OPTN
         </em>
         ,
         <em>
          SETX
         </em>
         , and
         <em>
          SQSTM1
         </em>
         genes, and others not associated with familial ALS, such as variants in the
         <em>
          TBK1
         </em>
         [
         <a href="#rid48">
          48
         </a>
         ],
         <em>
          ATXN2
         </em>
         [
         <a href="#rid49">
          49
         </a>
         ],
         <em>
          C21ORF2
         </em>
         [
         <a href="#rid50">
          50
         </a>
         ],
         <em>
          ITPR2
         </em>
         [
         <a href="#rid51">
          51
         </a>
         ],
         <em>
          NEK1
         </em>
         [
         <a href="#rid52">
          52
         </a>
         ], and
         <em>
          TP73
         </em>
         genes [
         <a href="#rid53">
          53
         </a>
         ] and duplications in the
         <em>
          SMN1
         </em>
         gene [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         In a 2017 meta-analysis of 111 studies that evaluated the frequencies of genetic variants of the most common ALS-related genes (
         <em>
          C9ORF72
         </em>
         ,
         <em>
          SOD1
         </em>
         ,
         <em>
          TARDBP
         </em>
         , and
         <em>
          FUS
         </em>
         ), there was a difference in the rates between European and Asian populations with sporadic ALS, as illustrated by the following observations [
         <a href="#rid55">
          55
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In European populations,
         <em>
          C9ORF72
         </em>
         repeat expansions were the most common (5.1 percent), followed by
         <em>
          SOD1
         </em>
         variants (1.2 percent),
         <em>
          TARDBP
         </em>
         variants (0.8 percent), and
         <em>
          FUS
         </em>
         variants (0.3 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In Asian populations,
         <em>
          SOD1
         </em>
         variants were the most common (1.5 percent), followed by
         <em>
          FUS
         </em>
         variants (0.9 percent),
         <em>
          C9ORF72
         </em>
         repeat expansions (0.3 percent), and
         <em>
          TARDBP
         </em>
         variants (0.2 percent).
        </p>
        <p>
        </p>
        <p>
         An earlier study found that rare or novel coding variants in known ALS genes, potentially pathogenic though not proven to be, were present in 28 percent of subjects with sporadic ALS, while variants in more than one ALS gene were found in 4 percent [
         <a href="#rid56">
          56
         </a>
         ]. Thus, these genes may function as Mendelian genes in familial ALS or as low-penetrance susceptibility factors in sporadic ALS. (See
         <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">
          "Familial amyotrophic lateral sclerosis"
         </a>
         .)
        </p>
        <p>
         Some of the candidate genes for ALS are associated with other neurodegenerative disorders:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Expanded polyglutamine repeats in
         <em>
          ATXN2
         </em>
         are better known as the cause of spinocerebellar ataxia type 2 (SCA2). One issue is that occasional patients with SCA2 have a predominant phenotype of motor neuron disease (MND), and further study is needed to establish whether
         <em>
          ATXN2
         </em>
         polyglutamine expansions are a risk factor for ALS [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">
          "Autosomal dominant spinocerebellar ataxias", section on 'SCA2'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <em>
          SMN
         </em>
         gene is better known for its role in spinal muscular atrophy, a disease of neonatal or childhood onset characterized by degeneration of the anterior horn cells in the spinal cord and motor nuclei in the lower brainstem. (See
         <a class="medical medical_review" href="/z/d/html/6146.html" rel="external">
          "Spinal muscular atrophy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The huntingtin (
         <em>
          HTT
         </em>
         ) gene is known for its role in Huntington disease, a neurodegenerative disorder associated with dementia and choreiform movements. Pathogenic expansions in the
         <em>
          HTT
         </em>
         gene have been observed in a small number of patients with ALS with frontotemporal dementia (ALS-FTD) [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Familial ALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial ALS accounts for 5 to 10 percent of all ALS cases [
         <a href="#rid59">
          59
         </a>
         ], with the rest being sporadic (idiopathic) in origin. Familial ALS is phenotypically and genetically heterogeneous. This topic is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">
          "Familial amyotrophic lateral sclerosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Geographic clusters
         </span>
         <span class="headingEndMark">
          —
         </span>
         High prevalence clusters of ALS are found in three regions of the western Pacific including Guam, West New Guinea, and the Kii Peninsula in Japan. The first cluster described was found in the indigenous people of Guam [
         <a href="#rid60">
          60,61
         </a>
         ]. The frequent association of ALS with parkinsonism and Alzheimer disease in this population has led to the designation of this entity as the amyotrophic lateral sclerosis-parkinsonism dementia complex (ALS-PDC).
        </p>
        <p>
         Although intensively studied since World War II, the cause of Guamanian ALS-PDC is unknown. One hypothesis proposed that the neurotoxicity was mediated by the local dietary consumption of cycad (
         <em>
          Cycas circinalis
         </em>
         ) [
         <a href="#rid62">
          62
         </a>
         ]. Cycad is rich in beta-N-methylamino-L-alanine (BMAA), an excitatory amino acid that has been shown to induce neuronal cell death in the rhesus monkey [
         <a href="#rid62">
          62
         </a>
         ]. Another hypothesis proposed that human consumption of the local flying fox, an animal that forages on the cycad, may have generated sufficiently high and cumulative levels of the neurotoxin to cause ALS-PDC. This hypothesis was supported by data demonstrating that the incidence of ALS-PDC on Guam fell significantly and in parallel with the loss of population of the flying fox [
         <a href="#rid63">
          63
         </a>
         ]. However, many remain unconvinced that cycad ingestion is the cause of Guamanian ALS [
         <a href="#rid64">
          64
         </a>
         ]. No single genetic defect, environmental toxin, or virus has been convincingly linked to these cases.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          PATHOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H2187779738">
         <span class="h2">
          Motor neuron degeneration
         </span>
         <span class="headingEndMark">
          —
         </span>
         ALS is characterized by motor neuron degeneration and death with gliosis replacing lost neurons. Cortical motor cells (pyramidal and Betz cells) disappear, leading to retrograde axonal loss and gliosis in the corticospinal tract. This gliosis results in the bilateral white matter changes sometimes seen in the brain magnetic resonance imaging (MRI) of patients with ALS. The spinal cord becomes atrophic. The ventral roots become thin, and there is a loss of large myelinated fibers in motor nerves. The affected muscles show denervation atrophy with evidence of reinnervation such as fiber type grouping.
        </p>
        <p class="headingAnchor" id="H1235273546">
         <span class="h2">
          Cerebral and other pathologic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional pathologic findings may include a loss of frontal or temporal cortical neurons, particularly in ALS with frontotemporal dementia (ALS-FTD). Mounting evidence from pathologic and genetic studies has led to the hypothesis that similar molecular pathways are involved in both disorders. (See
         <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">
          "Familial amyotrophic lateral sclerosis", section on 'C9ORF72 gene'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14138.html" rel="external">
          "Frontotemporal dementia: Epidemiology, pathology, and pathogenesis", section on 'Genetic factors'
         </a>
         .)
        </p>
        <p>
         Loss of nonmotor neurons whose axons contribute to the descending fronto-ponto-cerebellar tract has been reported [
         <a href="#rid65">
          65
         </a>
         ]. Pathology in nonmotor systems such as the posterior columns may be seen in familial forms of ALS. (See
         <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">
          "Familial amyotrophic lateral sclerosis"
         </a>
         .)
        </p>
        <p>
         While sensory involvement is not obvious clinically, the density of myelinated sensory fibers is reduced by approximately 30 percent in peripheral nerves [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Intracellular inclusions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intracellular inclusions in degenerating neurons and glia are frequent neuropathological findings of ALS.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Phosphorylated and nonphosphorylated neurofilament inclusions are prominent in spinal motor neurons; these may be associated with immunoreactive SOD1, even in sporadic ALS, or with nitric oxide.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bunina bodies are unique to ALS and consist of eosinophilic aggregates that are positive for cystatin C, a cysteine protease inhibitor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ubiquitinated inclusions are seen in ALS and several other neurodegenerative disorders, including FTD with ubiquitin positive/tau negative inclusions, but the ALS variety is unique in that it does not react with antibodies against neurofilament or tau. In both the familial or sporadic types of ALS-FTD, frontal and temporal lobe ubiquitinated inclusions are found in cortical neurons. Inclusions may be absent in some genetic forms of familial ALS [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TDP-43 accumulation and inclusion formation (ie, TDP-proteinopathy) is observed in most sporadic cases of ALS, FTD with ubiquitin-positive but tau-negative inclusions (see
         <a class="medical medical_review" href="/z/d/html/14138.html" rel="external">
          "Frontotemporal dementia: Epidemiology, pathology, and pathogenesis", section on 'FTLD-TDP'
         </a>
         ), and overlapping ALS with FTD [
         <a href="#rid68">
          68,69
         </a>
         ]. In addition, TDP-43 neuronal cytoplasmic inclusions are found in familial ALS (see
         <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">
          "Familial amyotrophic lateral sclerosis"
         </a>
         ) related to pathologic variants in a number of genes, which include the
         <em>
          TARDBP
         </em>
         gene that encodes for TDP-43, the
         <em>
          VAPB
         </em>
         gene, the
         <em>
          CHMP2B
         </em>
         gene, and to a lesser extent the
         <em>
          C9ORF72
         </em>
         gene; in postmortem tissue from patients with
         <em>
          C9ORF72
         </em>
         gene variants, TDP-43-positive inclusions appear to be less common than TDP-43-negative inclusions containing ubiquitin [
         <a href="#rid70">
          70
         </a>
         ]. However, TDP-43 inclusions are not found in
         <em>
          SOD1
         </em>
         -related familial ALS, with a few exceptions [
         <a href="#rid71">
          71,72
         </a>
         ]. These findings suggest a potentially important role for TDP-43 in the pathogenesis of ALS, non-
         <em>
          SOD1
         </em>
         ALS, ALS-FTD, and non-tau FTD. (See
         <a class="local">
          'Altered RNA processing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoreactive inclusions to FUS in spinal motor neurons have been detected in both sporadic and familial ALS, with the exception of those associated with
         <em>
          SOD1
         </em>
         variants [
         <a href="#rid73">
          73,74
         </a>
         ]. Earlier studies had not detected FUS-positive immunoreactive inclusions in patients with ALS except for those who had
         <em>
          FUS
         </em>
         variants.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The etiology of ALS is unknown. A number of potential mechanisms have been proposed including abnormal RNA processing, disorders of protein quality control, excitotoxicity, cytoskeletal derangements, mitochondrial dysfunction, viral infections, apoptosis, growth factor abnormalities, inflammatory responses, and others [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H107004749">
         <span class="h2">
          Altered RNA processing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mounting evidence supports the hypothesis that altered RNA processing and aggregation of abnormal proteins plays a major role in the pathogenesis of ALS [
         <a href="#rid76">
          76-79
         </a>
         ]. Variants in a number of genes that encode for RNA binding proteins, including TDP-43 and FUS, are known to cause ALS (see
         <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">
          "Familial amyotrophic lateral sclerosis"
         </a>
         ) and related neurodegenerative disorders. These proteins contain prion-like domains that have an intrinsic propensity to self-aggregation [
         <a href="#rid80">
          80
         </a>
         ]. They may normally function by assembling RNA into stress granules, which are temporary structures that help to regulate protein synthesis as part of the stress response [
         <a href="#rid81">
          81
         </a>
         ]. Variants in the prion-like domains of these proteins may promote excess incorporation of the proteins into stress granules that are resistant to degradation, and/or promote self-aggregation of abnormal RNA binding proteins (such as TDP-43), thereby leading to the formation of cytoplasmic inclusions (see
         <a class="local">
          'Intracellular inclusions'
         </a>
         above) and neurodegenerative disease. TDP-43 also normally functions by repressing the splicing of nonconserved regions of the genome known as cryptic exons [
         <a href="#rid82">
          82
         </a>
         ]. Depletion or aggregation of TDP-43 permits the splicing of cryptic exons into messenger RNA, which disrupts translation and leads to cell death [
         <a href="#rid83">
          83,84
         </a>
         ].
        </p>
        <p>
         The co-localization of TDP-43 and FUS in non-SOD1 ALS inclusions also supports the hypothesis that these DNA/RNA binding proteins are involved in the pathogenesis of non-
         <em>
          SOD1
         </em>
         forms of ALS. In vitro studies indicate that abnormal TDP-43 polypeptides have greater stability than those of the wildtype TDP-43 [
         <a href="#rid85">
          85
         </a>
         ], rather than lesser stability as occurs with abnormal SOD1 protein. In addition, abnormal TDP-43 shows enhanced binding to normal FUS/TLS. These findings imply that abnormal TDP-43 may disrupt normal FUS/TLS function and suggest a convergence of their pathogenic mechanisms in ALS [
         <a href="#rid85">
          85
         </a>
         ]. The TDP-43 and FUS proteins are normally found predominantly in the nucleus, where they are involved in RNA processing [
         <a href="#rid76">
          76,77
         </a>
         ]. Wildtype TDP-43 and FUS are transported to the nucleus by nuclear import receptors. However, variant forms of TDP-43 with C-terminal truncations lack the nuclear transport signal, causing mislocalization of the protein to the cytoplasm. Similarly, ALS-associated
         <em>
          FUS
         </em>
         variants impair nuclear transport and result in mislocalization to the cytoplasm. In sporadic ALS, aging may cause an accelerated increase in nuclear permeability and leakiness, with wildtype TDP-43 and FUS accumulating in the cytoplasm. The accumulation of TDP-43 and FUS in the cytoplasm may lead to neurodegeneration by disturbing the RNA quality control regulation or by the formation of stress granules  (
         <a class="graphic graphic_figure graphicRef143265" href="/z/d/graphic/143265.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         The ALS susceptibility factor ataxin 2 (see
         <a class="local">
          'Genetic susceptibility in sporadic ALS'
         </a>
         above), a constituent of stress granules and a putative RNA binding protein, may interact in the common pathologic pathway formed by TDP-43 and FUS  (
         <a class="graphic graphic_figure graphicRef77362" href="/z/d/graphic/77362.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid76">
          76
         </a>
         ]. By contrast, the pathologic process related to
         <em>
          SOD1
         </em>
         variants (see
         <a class="local">
          'SOD1-mediated toxicity'
         </a>
         below) may be independent of the TDP-43 and FUS pathologic cascade.
        </p>
        <p class="headingAnchor" id="H450667265">
         <span class="h3">
          C9ORF72 expansions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Expansion of a hexanucleotide repeat sequence in a noncoding region of the
         <em>
          C9ORF72
         </em>
         gene is the most common genetic cause of familial ALS and is also detected in occasional patients with sporadic ALS. Several mechanisms may account for the disease-causing effect of the genetic variant [
         <a href="#rid86">
          86
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The hexanucleotide repeat is made up of guanine-rich sequences, (GGGGCC)n, which can fold to form a secondary structure called a G-quadruplex [
         <a href="#rid87">
          87
         </a>
         ]. One hypothesis is that expansion of the hexanucleotide repeat sequence and G-quadruplex formation initiates a cascade of pathologic molecular alterations. These include formation of RNA/DNA hybrids called R-loops; production of abortive, defective RNA transcripts; and decreased production of full-length RNA transcripts. The defective RNA transcripts bind to a number of ribonucleoproteins including nucleolin, causing mislocalization of this essential protein within the nucleolus and leading to decreased cell viability. The
         <em>
          C9ORF72
         </em>
         hexanucleotide repeat expansion also interacts with Ran GTPase activating protein 1, which is an important regulator of nucleocytoplasmic transport, and may disrupt nucleocytoplasmic transport by clogging the nuclear membrane pores [
         <a href="#rid88">
          88,89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another hypothesis is that repeat-associated non-ATG translation (RAN translation) occurs within the expanded repeat sequence, leading to the production of toxic dipeptide repeat proteins that are aggregation prone and can interfere with multiple steps of RNA processing [
         <a href="#rid90">
          90-92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The expansion may lead to reduced expression of C9ORF72 protein levels, causing disease by a loss-of-function mechanism [
         <a href="#rid93">
          93-95
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         While not mutually exclusive, the contribution of each of these proposed mechanisms remains to be determined [
         <a href="#rid86">
          86,96
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          SOD1-mediated toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Superoxide dismutase type 1 (SOD1) is a metalloenzyme that catalyzes the conversion of toxic superoxide radicals to oxygen (O
         <sub>
          2
         </sub>
         ) and hydrogen peroxide (H
         <sub>
          2
         </sub>
         O
         <sub>
          2
         </sub>
         ). The discovery that variants in the
         <em>
          SOD1
         </em>
         gene are associated with some cases of familial ALS suggested that free radical toxicity may play a role in the process of neuronal cell death or apoptosis [
         <a href="#rid97">
          97
         </a>
         ]. In addition,
         <em>
          SOD1
         </em>
         variants have been found in 0.7 to 4 percent of patients with "sporadic" ALS [
         <a href="#rid98">
          98,99
         </a>
         ]. (See
         <a class="local">
          'Familial ALS'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Gain-of-function
         </span>
         <span class="headingEndMark">
          —
         </span>
         Damaging accumulation of superoxide could result if
         <em>
          SOD1
         </em>
         variants impaired its antioxidant function. However, several lines of evidence from cell culture and transgenic SOD1 mouse models of ALS have disproved the loss-of-function hypothesis [
         <a href="#rid100">
          100,101
         </a>
         ]. As an example, SOD1-knockout mice do not develop motor neuron disease (MND) [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
         It is more likely that
         <em>
          SOD1
         </em>
         pathogenic variants cause disease by a toxic gain-of-function [
         <a href="#rid102">
          102
         </a>
         ]. SOD1 has pro-oxidant as well as antioxidant activity, and the variant SOD1 protein could lead to oxidative injury by an increase in pro-oxidant pathways, including generation of hydroxyl radicals and nitration of tyrosine. In support of the toxic gain-of-function hypothesis, there is evidence that abnormal SOD1 directly stimulates NADPH oxidase (Nox) in transgenic mice and in human cell lines, and thereby causes overproduction of reactive oxygen species [
         <a href="#rid103">
          103,104
         </a>
         ].
        </p>
        <p>
         It has also been hypothesized that oxidation leads to post-translational modifications of wildtype SOD1 protein, causing it to misfold and thereby gain toxic properties similar to abnormal SOD1 [
         <a href="#rid105">
          105
         </a>
         ]. This mechanism could then be the cause of the majority of cases of classic ALS, which lack
         <em>
          SOD1
         </em>
         pathogenic variants.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Protein misfolding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another hypothesis is that abnormal SOD1 induces protein aggregates that are potentially toxic to motor neurons [
         <a href="#rid106">
          106,107
         </a>
         ].
        </p>
        <p>
         However, accumulation of disulfide cross-linked aggregates of abnormal SOD1 protein may be a secondary manifestation of end-stage disease rather than a primary event in the pathogenesis of ALS [
         <a href="#rid108">
          108
         </a>
         ]. This hypothesis is supported by a study in transgenic mice, which found that a number of pathologic abnormalities (eg, Golgi apparatus degradation, endplate denervation, reactive astrogliosis) occurred before the levels of aggregated forms of abnormal SOD1 increased [
         <a href="#rid108">
          108
         </a>
         ]. Elevated levels of abnormal SOD1 protein were observed only in the final stages of the disease.
        </p>
        <p>
         Nevertheless, very low levels of SOD1 aggregates may be sufficient to mediate toxicity [
         <a href="#rid108">
          108
         </a>
         ]. Another possibility is that other forms of SOD1 may be pathologic at early stages of disease. The initial step in the SOD protein assembly pathway is folding of the protein into a homodimeric apo state, and this apo-SOD1 protein is typically associated with severe instability in abnormal SOD1 proteins [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
         The conformational instability of ALS-linked SOD1 variants may be related to reductional cleavage of the disulfide bond that normally links two cysteine subunits (C57-C146), resulting in an increased propensity of the protein to unfold or misfold and aggregate [
         <a href="#rid110">
          110
         </a>
         ]. More unstable and therefore short-lived variants unfold and become prone to aggregation. In mice, unfolded or misfolded disulfide-reduced SOD1 variants showed higher steady-state levels in the spinal cord and brain than in peripheral organs, suggesting inefficient recognition and degradation in the central nervous system (CNS) [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p>
         In a study that analyzed SOD1 from 29 patients with 22 different variants, lower levels (ie, greater instability) of abnormal SOD1 were associated with shorter disease survival time [
         <a href="#rid111">
          111
         </a>
         ]. Thus, patients with less stable SOD1 who accumulate less abnormal protein have a more rapid disease course. However, levels of abnormal SOD1 were not associated with age at disease onset.
        </p>
        <p>
         These results suggest that the misfolded unstable forms of SOD1 contribute to toxicity and disease progression but not directly to onset, implying different mechanisms of disease onset and progression [
         <a href="#rid112">
          112
         </a>
         ]. Supporting this viewpoint is experimental evidence that suppressing abnormal SOD1 synthesis selectively in motor neurons delays onset of disease in mice expressing abnormal SOD1 [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H28870207">
         <span class="h3">
          Non-neuronal cell types influence disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data from ALS murine models and human ALS-induced pluripotent stem cells (iPSC) suggest that non-neuronal cells may also be involved in the pathogenesis of ALS [
         <a href="#rid114">
          114-119
         </a>
         ]. Supporting evidence comes from studies in mice with abnormal SOD1 show that cell types besides motor neurons play a role in disease onset and progression [
         <a href="#rid120">
          120-123
         </a>
         ]. In chimeric ALS mice, simple expression of the pathologic variant SOD1 in neurons/motor neurons was insufficient to lead to neuronal death without concomitant expression in glial cells. Wildtype motor neurons appeared to undergo degeneration when surrounded by abnormal SOD1 astroglia. Conversely, wildtype non-neuronal cells surrounding motor neurons expressing abnormal SOD1 extended the survival of such motor neurons [
         <a href="#rid120">
          120
         </a>
         ] and increased disease-free life [
         <a href="#rid124">
          124
         </a>
         ]. Likewise, the deletion of abnormal SOD1 from oligodendrocytes showed a protective effect on motor neurons and improved survival in animal models [
         <a href="#rid123">
          123
         </a>
         ]. Other reports demonstrated that the reduction of abnormal SOD1 selectively from astrocytes in mice [
         <a href="#rid122">
          122
         </a>
         ] or in microglia [
         <a href="#rid125">
          125
         </a>
         ] resulted in a slowing of disease progression but had no effects on disease onset.
        </p>
        <p class="headingAnchor" id="H2160745">
         <span class="h2">
          Inflammatory responses
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of studies have shown that inflammatory processes are involved in ALS disease progression and neuronal death [
         <a href="#rid125">
          125-132
         </a>
         ]. These inflammatory responses include activation of microglia and astrocytes as well as infiltration of natural killer cells, peripheral T cells, and monocytes into the CNS. Many of these reports have focused on microglia, which are immune-modulating cells of the CNS. Once activated, microglia elaborate a host of factors, including nitric oxide, oxygen radicals, cytokines, glutamate, and others that may play roles in part of the cascade leading to motor neuron cell death [
         <a href="#rid125">
          125,133
         </a>
         ]. Several lines of evidence suggest that microglia are relevant to disease progression in ALS models [
         <a href="#rid104">
          104,134,135
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Excitotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The excitotoxicity hypothesis postulates that excessive levels of the excitatory neurotransmitter glutamate may initiate a cascade resulting in cellular death of motor neurons in ALS. Excessive activation of glutamate receptors may lead to increased entry of calcium into cells. In turn, intracellular calcium may trigger a cascade of events that causes neuronal cell death via lipid peroxidation, nucleic acid damage, and mitochondrial disruption.
        </p>
        <p>
         The role of excitotoxicity in ALS remains unsettled. In support of the excitotoxicity hypothesis is the finding of elevated glutamate levels in the cerebrospinal fluid of patients with sporadic ALS [
         <a href="#rid136">
          136,137
         </a>
         ]. In addition, defects in glutamate transport that may contribute to excessive extracellular glutamate have been noted in 80 percent of patients with sporadic ALS and in the transgenic SOD1 mouse model of ALS [
         <a href="#rid138">
          138-140
         </a>
         ]. These defects involve transmembrane glutamate transporters located on neurons and particularly on glial cells that are normally responsible for rapid inactivation of glutamate after its release.
        </p>
        <p>
         One longstanding hypothesis suggests that nonfunctional, truncated forms of one glutamate transporter subtype (EAAT2), the primary glutamate transporter on astrocytes, may be particularly prominent in ALS tissues [
         <a href="#rid138">
          138
         </a>
         ]. However, some of these truncated forms have also been found in normal tissue. Additionally, it appears that a splice-variant of this protein (EAAT2b) may actually be upregulated in ALS, particularly in neurons. These findings suggest that there may be a potential compensatory effect to increase other glutamate transporters in the presence of elevated extracellular glutamate [
         <a href="#rid141">
          141
         </a>
         ].
        </p>
        <p>
         Glutamate receptor dysfunction is another potential mechanism for excitotoxicity. A number of postsynaptic glutamate receptors may be involved in this process, including the N-methyl-D-aspartic acid (NMDA) receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor, the kainate receptor, and the G-protein-coupled receptor. As an example, defective editing of messenger RNA that encodes for a subunit of glutamate AMPA receptors has been found in spinal motor neurons of patients with ALS [
         <a href="#rid142">
          142
         </a>
         ]. This glutamate editing defect has been linked to increased permeability to calcium ions through this AMPA receptor subtype and may result in downstream effects leading to neuronal death.
        </p>
        <p>
         Perhaps some of the best evidence suggesting that glutamate excitotoxicity may have a role in ALS disease progression is the demonstration that the antiglutaminergic drug
         <a class="drug drug_general" data-topicid="9865" href="/z/d/drug information/9865.html" rel="external">
          riluzole
         </a>
         improves survival in patients with the disease. (See
         <a class="medical medical_review" href="/z/d/html/5128.html" rel="external">
          "Disease-modifying treatment of amyotrophic lateral sclerosis", section on 'Riluzole'
         </a>
         .)
        </p>
        <p>
         However, other drugs affecting glutamate neurotransmission have not been successful in clinical trials [
         <a href="#rid143">
          143
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Cytoskeletal derangements
         </span>
         <span class="headingEndMark">
          —
         </span>
         The intracellular neurofilament inclusions found within degenerating motor neurons may be involved in the pathogenesis of ALS [
         <a href="#rid144">
          144,145
         </a>
         ]. Neurofilaments are a type of intermediate filament expressed at high levels by motor neurons, and they are formed by the assembly of light, medium, and heavy subunits. They normally function as structural elements that perform vital roles in maintaining cell shape, axonal caliber, and axonal transport.
        </p>
        <p>
         Deranged neurofilaments could disrupt axonal transport and cause axonal strangulation [
         <a href="#rid146">
          146
         </a>
         ]. Variants in the neurofilament heavy subunit gene have been found in sporadic and familial forms of ALS [
         <a href="#rid147">
          147,148
         </a>
         ]. Reduction in the light subunit mRNA levels was detected in spinal motor neurons of ALS patients [
         <a href="#rid149">
          149
         </a>
         ]. Overexpression or deletion of neurofilament subunits in transgenic mice resulted in motor neuron degeneration and axonal swellings with neurofilaments similar to those seen in ALS patients [
         <a href="#rid146">
          146,150
         </a>
         ]. Intracellular neurofilament inclusions may be a potential biomarker in ALS, but whether they represent a cause or effect of neuronal degeneration remains uncertain [
         <a href="#rid151">
          151,152
         </a>
         ].
        </p>
        <p>
         Inhibition of axonal transport may be a cause of motor neuron degeneration. Defects in the dynein-dynactin complex, a molecular motor responsible for axonal transport along microtubules, have been linked with motor degeneration in the mouse [
         <a href="#rid153">
          153
         </a>
         ], and a variant form of dynactin has been linked with a progressive lower motor neuron disorder in a human family [
         <a href="#rid154">
          154,155
         </a>
         ].
        </p>
        <p>
         Impaired microtubule dynamics have been widely implicated in neurodegeneration. While disruption of TDP-43 nuclear function affects the processing of numerous RNA targets, a link between increased motor neuron vulnerability in ALS and suppression of stathmin-2, a tubulin-binding protein previously established to affect microtubule dynamics, has been suggested as a possible common role for mechanisms of axon dysfunction in sporadic ALS [
         <a href="#rid156">
          156,157
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Mitochondrial dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mitochondrial dysfunction occurs early in the transgenic SOD1 mouse model, preceding other evidence of motor neuron damage [
         <a href="#rid158">
          158
         </a>
         ]. Data suggest that a selective recruitment of abnormal SOD1 to spinal cord mitochondria, when compared with less affected tissues, may explain the abundant pathology in the spinal cord of the transgenic SOD1 mouse [
         <a href="#rid159">
          159
         </a>
         ]. Human biochemical and morphologic studies demonstrate consistent mitochondrial abnormalities [
         <a href="#rid160">
          160,161
         </a>
         ]. These abnormalities may be the result of oxidative stress and, in turn, may potentiate it.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Viral infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Poliovirus, enteroviruses, and exogenous or inherited endogenous retroviruses have been proposed to be causative agents of ALS [
         <a href="#rid162">
          162-166
         </a>
         ]. However, exhaustive studies have never confirmed a clear etiologic relationship. Human immunodeficiency virus (HIV) infection and Lyme disease rarely cause an ALS-like syndrome [
         <a href="#rid167">
          167,168
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86984.html" rel="external">
          "Acute and early HIV infection: Clinical manifestations and diagnosis", section on 'Neurologic findings'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Apoptosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Apoptosis or programmed cell death cascades have been implicated in several studies of the variant SOD1 mouse model of ALS. These reports have shown a number of the hallmarks of apoptosis including DNA fragmentation, caspase activation, and altered expression of the antiapoptotic protein Bcl-2 [
         <a href="#rid106">
          106,169
         </a>
         ]. One report of 87 patients with sporadic ALS identified multiple variants in the
         <em>
          TP73
         </em>
         gene [
         <a href="#rid53">
          53
         </a>
         ]. These variants were associated with impaired normal cellular differentiation, increased apoptosis, and reduced motor neuron survival.
        </p>
        <p>
         Some evidence suggests that apoptosis may be a late pathway for motor neuron degeneration in ALS, but its importance in ALS has been controversial [
         <a href="#rid170">
          170,171
         </a>
         ]. However, one study found that genetic deletion of the mitochondrial apoptotic pathway in a mouse model of ALS halted neuronal loss and prevented axonal degeneration, symptom onset, and paralysis [
         <a href="#rid172">
          172
         </a>
         ]. In addition, survival was extended. These findings suggest that inhibition of apoptosis is a possible therapeutic strategy for ALS.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Growth factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Growth factors such as brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), insulin-like growth factor (IGF-1), and vascular endothelial growth factor (VEGF) have been studied previously both for their possible role in the etiology of ALS and for their therapeutic potential [
         <a href="#rid173">
          173-180
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2144843129">
         <span class="h1">
          CLINICAL SPECTRUM OF DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Historically, ALS was identified as a clinical syndrome distinguishable from other motor neuron diseases (MNDs) such as primary lateral sclerosis, progressive muscular atrophy, and progressive bulbar palsy, based upon the location of first symptom and the extent to which anterior horn cells or corticomotor neurons are initially involved. However, it is increasingly evident that ALS is clinically and pathophysiologically diverse [
         <a href="#rid181">
          181
         </a>
         ], with clear overlap with frontotemporal dementia (FTD) [
         <a href="#rid182">
          182,183
         </a>
         ]. Multiple genetic variants may lead to a similar clinical phenotype, while a single variant may be associated with pure ALS, ALS with FTD (ALS-FTD), or pure FTD. These conditions exist on a clinicopathologic spectrum, with potentially different etiologies that share a final common pathway leading to upper and lower motor neuron degeneration. It is therefore appropriate to place ALS among other neurodegenerative diseases, such as Alzheimer disease, Parkinson disease, and Huntington disease. (See
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Spectrum of motor neuron disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H897701184">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118906.html" rel="external">
          "Society guideline links: Motor neuron disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28871029">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Amyotrophic lateral sclerosis (ALS) is classified as either sporadic or familial. Sporadic forms account for approximately 90 percent of ALS cases, while familial forms make up the remaining 10 percent. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">
          "Familial amyotrophic lateral sclerosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Incidence rates for ALS in Europe and North America range between 1.5 and 2.7 per 100,000 person-years, while prevalence rates range between 2.7 and 7.4 per 100,000 person-years. The incidence of ALS increases with each decade, especially after age 40 years.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The male-to-female ratio is approximately 1.3 to 1.5 for sporadic ALS, although the ratio becomes closer to unity in the age group over 70 years. (See
         <a class="local">
          'Incidence and prevalence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Established risk factors for ALS are age and family history. Cigarette smoking also appears to be a risk factor for ALS. There are weak or conflicting data for other nongenetic risk factors, a list that includes military service, agricultural work, factory work, heavy manual labor, exposure to welding or soldering, exposure to heavy metal, work in the plastics industry, repetitive muscle use, athleticism, playing professional soccer, trauma, and electrical shock. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic susceptibilities
         </strong>
         – Several genes that act as Mendelian genes in familial ALS (
         <em>
          SOD1
         </em>
         ,
         <em>
          C9ORF72
         </em>
         ,
         <em>
          FUS
         </em>
         ,
         <em>
          TARDBP
         </em>
         ,
         <em>
          ANG
         </em>
         ,
         <em>
          OPTN
         </em>
         , and
         <em>
          SETX
         </em>
         ) may also be low-penetrance susceptibility factors in sporadic ALS. Expansions in the
         <em>
          ATXN2
         </em>
         gene and duplications of the
         <em>
          SMN1
         </em>
         gene are also associated with an increased risk of ALS. (See
         <a class="local">
          'Genetic susceptibility in sporadic ALS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathologic findings
         </strong>
         – ALS is characterized by motor neuron degeneration and death with gliosis replacing lost neurons. Degenerating neurons and glia show intracellular inclusions. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cortical motor cells (pyramidal and Betz cells) degenerate, leading to retrograde axonal loss and gliosis in the corticospinal tract.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The spinal cord becomes atrophic. The ventral roots become thin, and there is a loss of large, myelinated fibers in motor nerves.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The affected muscles show denervation atrophy with evidence of reinnervation such as fiber type grouping.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiologies
         </strong>
         – The development of ALS appears to result from a complex interplay between genes and environmental factors that trigger several downstream biochemical cascades. Proposed mechanisms include abnormalities in RNA metabolism, SOD1-mediated toxicity, excitotoxicity, cytoskeletal derangements, mitochondrial dysfunction, viral infections, apoptosis, growth factor abnormalities, and inflammatory responses. (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rowland LP. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol 2001; 58:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci 2001; 191:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010; 81:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan H, Rechtman L, Wagner L, Kaye WE. Amyotrophic lateral sclerosis surveillance in Baltimore and Philadelphia. Muscle Nerve 2015; 51:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta P, Kaye W, Raymond J, et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2014. MMWR Morb Mortal Wkly Rep 2018; 67:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camacho-Soto A, Searles Nielsen S, Faust IM, et al. Incidence of amyotrophic lateral sclerosis in older adults. Muscle Nerve 2022; 66:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfson C, Gauvin DE, Ishola F, Oskoui M. Global Prevalence and Incidence of Amyotrophic Lateral Sclerosis: A Systematic Review. Neurology 2023; 101:e613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts AL, Johnson NJ, Chen JT, et al. Race/ethnicity, socioeconomic status, and ALS mortality in the United States. Neurology 2016; 87:2300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology 2007; 68:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiò A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013; 41:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chancellor AM, Warlow CP. Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J Neurol Neurosurg Psychiatry 1992; 55:1106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noonan CW, White MC, Thurman D, Wong LY. Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998. Neurology 2005; 64:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy M, Quinn S, Young J, et al. Increasing incidence of ALS in Canterbury, New Zealand: a 22-year study. Neurology 2008; 71:1889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiò A, Magnani C, Schiffer D. Gompertzian analysis of amyotrophic lateral sclerosis mortality in Italy, 1957-1987; application to birth cohorts. Neuroepidemiology 1995; 14:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology 2009; 73:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallo V, Bueno-De-Mesquita HB, Vermeulen R, et al. Smoking and risk for amyotrophic lateral sclerosis: analysis of the EPIC cohort. Ann Neurol 2009; 65:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutedja NA, Veldink JH, Fischer K, et al. Lifetime occupation, education, smoking, and risk of ALS. Neurology 2007; 69:1508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhan Y, Fang F. Smoking and amyotrophic lateral sclerosis: A mendelian randomization study. Ann Neurol 2019; 85:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bandres-Ciga S, Noyce AJ, Hemani G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol 2019; 85:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armon C, Kurland LT, Daube JR, O'Brien PC. Epidemiologic correlates of sporadic amyotrophic lateral sclerosis. Neurology 1991; 41:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felmus MT, Patten BM, Swanke L. Antecedent events in amyotrophic lateral sclerosis. Neurology 1976; 26:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longstreth WT, McGuire V, Koepsell TD, et al. Risk of amyotrophic lateral sclerosis and history of physical activity: a population-based case-control study. Arch Neurol 1998; 55:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarmeas N, Shih T, Stern Y, et al. Premorbid weight, body mass, and varsity athletics in ALS. Neurology 2002; 59:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiò A, Benzi G, Dossena M, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005; 128:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veldink JH, Kalmijn S, Groeneveld GJ, et al. Physical activity and the association with sporadic ALS. Neurology 2005; 64:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perl DP, Gajdusek DC, Garruto RM, et al. Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science 1982; 217:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344:1688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell JD. Heavy metals and trace elements in amyotrophic lateral sclerosis. Neurol Clin 1987; 5:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamel F, Umbach DM, Munsat TL, et al. Lead exposure and amyotrophic lateral sclerosis. Epidemiology 2002; 13:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gresham LS, Molgaard CA, Golbeck AL, Smith R. Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case-control study. Neuroepidemiology 1986; 5:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology 2003; 61:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horner RD, Kamins KG, Feussner JR, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 2003; 61:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisskopf MG, O'Reilly EJ, McCullough ML, et al. Prospective study of military service and mortality from ALS. Neurology 2005; 64:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallo V, Wark PA, Jenab M, et al. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology 2013; 80:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fondell E, Fitzgerald KC, Falcone GJ, et al. Early-onset alopecia and amyotrophic lateral sclerosis: a cohort study. Am J Epidemiol 2013; 178:1146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seals RM, Hansen J, Gredal O, Weisskopf MG. Physical Trauma and Amyotrophic Lateral Sclerosis: A Population-Based Study Using Danish National Registries. Am J Epidemiol 2016; 183:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eaglehouse YL, Talbott EO, Chang Y, Kuller LH. Participation in Physical Activity and Risk for Amyotrophic Lateral Sclerosis Mortality Among Postmenopausal Women. JAMA Neurol 2016; 73:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su FC, Goutman SA, Chernyak S, et al. Association of Environmental Toxins With Amyotrophic Lateral Sclerosis. JAMA Neurol 2016; 73:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tseng CC, Chang SJ, Tsai WC, et al. Increased Incidence of Amyotrophic Lateral Sclerosis in Polymyositis: A Nationwide Cohort Study. Arthritis Care Res (Hoboken) 2017; 69:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visser AE, Rooney JPK, D'Ovidio F, et al. Multicentre, cross-cultural, population-based, case-control study of physical activity as risk factor for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2018; 89:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen GX, Mannetje A', Douwes J, et al. Associations of Occupational Exposures to Electric Shocks and Extremely Low-Frequency Magnetic Fields With Motor Neurone Disease. Am J Epidemiol 2021; 190:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daneshvar DH, Mez J, Alosco ML, et al. Incidence of and Mortality From Amyotrophic Lateral Sclerosis in National Football League Athletes. JAMA Netw Open 2021; 4:e2138801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beard JD, Steege AL, Ju J, et al. Mortality from Amyotrophic Lateral Sclerosis and Parkinson's Disease Among Different Occupation Groups - United States, 1985-2011. MMWR Morb Mortal Wkly Rep 2017; 66:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson K, Bjornevik K, Abu-Ali G, et al. The human gut microbiota in people with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2021; 22:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boddy SL, Giovannelli I, Sassani M, et al. The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS). BMC Med 2021; 19:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose MR. Gulf War service is an uncertain trigger for ALS. Neurology 2003; 61:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leblond CS, Kaneb HM, Dion PA, Rouleau GA. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp Neurol 2014; 262 Pt B:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015; 347:1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lattante S, Conte A, Zollino M, et al. Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease. Neurology 2012; 79:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rheenen W, Shatunov A, Dekker AM, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet 2016; 48:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Es MA, Van Vught PW, Blauw HM, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol 2007; 6:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenna KP, van Doormaal PT, Dekker AM, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet 2016; 48:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell KL, Downie JM, Gibson SB, et al. Pathogenic Effect of TP73 Gene Variants in People With Amyotrophic Lateral Sclerosis. Neurology 2021; 97:e225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang XB, Cui NH, Gao JJ, et al. SMN1 duplications contribute to sporadic amyotrophic lateral sclerosis susceptibility: evidence from a meta-analysis. J Neurol Sci 2014; 340:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zou ZY, Zhou ZR, Che CH, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2017; 88:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cady J, Allred P, Bali T, et al. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol 2015; 77:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischbeck KH, Pulst SM. Amyotrophic lateral sclerosis and spinocerebellar ataxia 2. Neurology 2011; 76:2050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewan R, Chia R, Ding J, et al. Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron 2021; 109:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82:623.
          </a>
         </li>
         <li class="breakAll">
          Zimmerman HM. Monthly report to the medical officer in command. United States Navy; Medical Research Unit No. 2, 1945.
         </li>
         <li>
          <a class="nounderline abstract_t">
           KURLAND LT, MULDER DW. Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution, with special reference to the Mariana Islands, including clinical and pathologic observations. Neurology 1954; 4:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer PS, Nunn PB, Hugon J, et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 1987; 237:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox PA, Sacks OW. Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology 2002; 58:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steele JC, McGeer PL. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 2008; 70:1984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parvizi J, Anderson SW, Martin CO, et al. Pathological laughter and crying: a link to the cerebellum. Brain 2001; 124:1708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley WG, Good P, Rasool CG, Adelman LS. Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis. Ann Neurol 1983; 14:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arisato T, Okubo R, Arata H, et al. Clinical and pathological studies of familial amyotrophic lateral sclerosis (FALS) with SOD1 H46R mutation in large Japanese families. Acta Neuropathol 2003; 106:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geser F, Martinez-Lage M, Robinson J, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009; 66:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ince PG, Highley JR, Kirby J, et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol 2011; 122:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gijselinck I, Van Langenhove T, van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 2012; 11:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okamoto Y, Ihara M, Urushitani M, et al. An autopsy case of SOD1-related ALS with TDP-43 positive inclusions. Neurology 2011; 77:1993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sumi H, Kato S, Mochimaru Y, et al. Nuclear TAR DNA binding protein 43 expression in spinal cord neurons correlates with the clinical course in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2009; 68:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deng HX, Zhai H, Bigio EH, et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol 2010; 67:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tyzack GE, Luisier R, Taha DM, et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain 2019; 142:2572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters OM, Ghasemi M, Brown RH Jr. Emerging mechanisms of molecular pathology in ALS. J Clin Invest 2015; 125:1767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito D, Suzuki N. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS. Neurology 2011; 77:1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buratti E. TDP-43 and FUS in ALS/FTLD: will common pathways fit all? Neurology 2011; 77:1588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma A, Tandan R. RNA quality control and protein aggregates in amyotrophic lateral sclerosis: a review. Muscle Nerve 2013; 47:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013; 495:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell 2011; 147:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolozin B. Regulated protein aggregation: stress granules and neurodegeneration. Mol Neurodegener 2012; 7:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 2015; 349:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma XR, Prudencio M, Koike Y, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature 2022; 603:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown AL, Wilkins OG, Keuss MJ, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 2022; 603:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ling SC, Albuquerque CP, Han JS, et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A 2010; 107:13318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heutink P, Jansen IE, Lynes EM. C9orf72; abnormal RNA expression is the key. Exp Neurol 2014; 262 Pt B:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 2014; 507:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang K, Donnelly CJ, Haeusler AR, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 2015; 525:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Underwood E. NEUROSCIENCE. Plugged pores may underlie some ALS, dementia cases. Science 2015; 349:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwon I, Xiang S, Kato M, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 2014; 345:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mizielinska S, Grönke S, Niccoli T, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 2014; 345:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013; 339:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belzil VV, Bauer PO, Prudencio M, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol 2013; 126:895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciura S, Lattante S, Le Ber I, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol 2013; 74:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waite AJ, Bäumer D, East S, et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol Aging 2014; 35:1779.e5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul JW, Gitler AD. Cell Biology. Clogging information flow in ALS. Science 2014; 345:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 2006; 6:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiò A, Traynor BJ, Lombardo F, et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology 2008; 70:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurney ME. Transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med 1994; 331:1721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reaume AG, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996; 13:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurney ME. Transgenic animal models of familial amyotrophic lateral sclerosis. J Neurol 1997; 244 Suppl 2:S15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harraz MM, Marden JJ, Zhou W, et al. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest 2008; 118:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boillée S, Cleveland DW. Revisiting oxidative damage in ALS: microglia, Nox, and mutant SOD1. J Clin Invest 2008; 118:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabashi E, Valdmanis PN, Dion P, Rouleau GA. Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis? Ann Neurol 2007; 62:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durham HD, Roy J, Dong L, Figlewicz DA. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol 1997; 56:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleveland DW, Liu J. Oxidation versus aggregation - how do SOD1 mutants cause ALS? Nat Med 2000; 6:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karch CM, Prudencio M, Winkler DD, et al. Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. Proc Natl Acad Sci U S A 2009; 106:7774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindberg MJ, Tibell L, Oliveberg M. Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state. Proc Natl Acad Sci U S A 2002; 99:16607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jonsson PA, Graffmo KS, Andersen PM, et al. Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain 2006; 129:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato T, Nakanishi T, Yamamoto Y, et al. Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology 2005; 65:1954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamanaka K, Cleveland DW. Determinants of rapid disease progression in ALS. Neurology 2005; 65:1859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005; 11:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer K, Ferraiuolo L, Miranda CJ, et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci U S A 2014; 111:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall CE, Yao Z, Choi M, et al. Progressive Motor Neuron Pathology and the Role of Astrocytes in a Human Stem Cell Model of VCP-Related ALS. Cell Rep 2017; 19:1739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madill M, McDonagh K, Ma J, et al. Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms. Mol Brain 2017; 10:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varcianna A, Myszczynska MA, Castelli LM, et al. Micro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS. EBioMedicine 2019; 40:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao C, Devlin AC, Chouhan AK, et al. Mutant C9orf72 human iPSC-derived astrocytes cause non-cell autonomous motor neuron pathophysiology. Glia 2020; 68:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferraiuolo L, Meyer K, Sherwood TW, et al. Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc Natl Acad Sci U S A 2016; 113:E6496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003; 302:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borchelt DR. Amyotrophic lateral sclerosis--are microglia killing motor neurons? N Engl J Med 2006; 355:1611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamanaka K, Chun SJ, Boillee S, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008; 11:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang SH, Li Y, Fukaya M, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci 2013; 16:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamanaka K, Boillee S, Roberts EA, et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci U S A 2008; 105:7594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boillée S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006; 312:1389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neusch C, Bähr M, Schneider-Gold C. Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease? Muscle Nerve 2007; 35:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 2011; 10:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beers DR, Henkel JS, Zhao W, et al. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A 2008; 105:15558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lincecum JM, Vieira FG, Wang MZ, et al. From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet 2010; 42:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007; 10:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butovsky O, Siddiqui S, Gabriely G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 2012; 122:3063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frakes AE, Ferraiuolo L, Haidet-Phillips AM, et al. Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron 2014; 81:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Rourke JG, Bogdanik L, Yáñez A, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science 2016; 351:1324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao W, Beers DR, Henkel JS, et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 2010; 58:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci U S A 2010; 107:13046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995; 4:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunlop J, Beal McIlvain H, She Y, Howland DS. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 2003; 23:1688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maragakis NJ, Dykes-Hoberg M, Rothstein JD. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol 2004; 55:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004; 427:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maragakis NJ, de Carvalho M, Weiss MD. Therapeutic targeting of ALS pathways: Refocusing an incomplete picture. Ann Clin Transl Neurol 2023; 10:1948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrison BM, Morrison JH, Gordon JW. Superoxide dismutase and neurofilament transgenic models of amyotrophic lateral sclerosis. J Exp Zool 1998; 282:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin H, Schlaepfer WW. Role of neurofilament aggregation in motor neuron disease. Ann Neurol 2006; 60:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard JF, Côté F, Julien JP. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 1995; 375:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3:1757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Chalabi A, Andersen PM, Nilsson P, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong NK, He BP, Strong MJ. Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). J Neuropathol Exp Neurol 2000; 59:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Côté F, Collard JF, Julien JP. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993; 73:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Julien JP, Beaulieu JM. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci 2000; 180:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 2020; 95:e59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaMonte BH, Wallace KE, Holloway BA, et al. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002; 34:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puls I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003; 33:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puls I, Oh SJ, Sumner CJ, et al. Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol 2005; 57:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melamed Z, López-Erauskin J, Baughn MW, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci 2019; 22:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klim JR, Williams LA, Limone F, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci 2019; 22:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998; 18:3241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Lillo C, Jonsson PA, et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 2004; 43:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassarino DS, Bennett JP Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Brain Res Rev 1999; 29:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005; 58:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanson NR, Fox SA, Mastaglia FL. Search for persistent infection with poliovirus or other enteroviruses in amyotrophic lateral sclerosis-motor neurone disease. Neuromuscul Disord 1995; 5:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nix WA, Berger MM, Oberste MS, et al. Failure to detect enterovirus in the spinal cord of ALS patients using a sensitive RT-PCR method. Neurology 2004; 62:1372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jubelt B, Lipton HL. ALS: persistent scientists do not find persisting enteroviruses. Neurology 2004; 62:1250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steele AJ, Al-Chalabi A, Ferrante K, et al. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology 2005; 64:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormick AL, Brown RH Jr, Cudkowicz ME, et al. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology 2008; 70:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halperin JJ. Nervous system Lyme disease. J Neurol Sci 1998; 153:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moulignier A, Moulonguet A, Pialoux G, Rozenbaum W. Reversible ALS-like disorder in HIV infection. Neurology 2001; 57:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spooren WP, Hengerer B. DNA laddering and caspase 3-like activity in the spinal cord of a mouse model of familial amyotrophic lateral sclerosis. Cell Mol Biol (Noisy-le-grand) 2000; 46:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999; 58:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He BP, Strong MJ. Motor neuronal death in sporadic amyotrophic lateral sclerosis (ALS) is not apoptotic. A comparative study of ALS and chronic aluminium chloride neurotoxicity in New Zealand white rabbits. Neuropathol Appl Neurobiol 2000; 26:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reyes NA, Fisher JK, Austgen K, et al. Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J Clin Invest 2010; 120:3673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 1999; 52:1427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol 1996; 39:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997; 49:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998; 51:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terry PD, Kamel F, Umbach DM, et al. VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS). J Neurogenet 2004; 18:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005; 8:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner MR, Swash M. The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey. J Neurol Neurosurg Psychiatry 2015; 86:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013; 12:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campos CF, Gromicho M, Uysal H, et al. Family history of neurodegenerative disorders in patients with amyotrophic lateral sclerosis: population-based case-control study. J Neurol Neurosurg Psychiatry 2020; 91:671.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5156 Version 57.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11255459" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11676986" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The epidemiology of motor neuron diseases: a review of recent studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19710046" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Incidence of amyotrophic lateral sclerosis in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25298019" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Amyotrophic lateral sclerosis surveillance in Baltimore and Philadelphia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29470458" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prevalence of Amyotrophic Lateral Sclerosis - United States, 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35678083" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Incidence of amyotrophic lateral sclerosis in older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37308302" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Global Prevalence and Incidence of Amyotrophic Lateral Sclerosis: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27742817" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Race/ethnicity, socioeconomic status, and ALS mortality in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17389304" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Ethnic variation in the incidence of ALS: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23860588" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1479386" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15824349" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19047561" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Increasing incidence of ALS in Canterbury, New Zealand: a 22-year study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8569998" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Gompertzian analysis of amyotrophic lateral sclerosis mortality in Italy, 1957-1987; application to birth cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19917993" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Smoking may be considered an established risk factor for sporadic ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19399866" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Smoking and risk for amyotrophic lateral sclerosis: analysis of the EPIC cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17923612" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Lifetime occupation, education, smoking, and risk of ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30786056" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Smoking and amyotrophic lateral sclerosis: A mendelian randomization study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30723964" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2067636" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Epidemiologic correlates of sporadic amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/946326" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Antecedent events in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9482362" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Risk of amyotrophic lateral sclerosis and history of physical activity: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12221178" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Premorbid weight, body mass, and varsity athletics in ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15634730" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15668420" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Physical activity and the association with sporadic ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7112111" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11386269" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3550416" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Heavy metals and trace elements in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11964933" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Lead exposure and amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3748267" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14504316" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Excess incidence of ALS in young Gulf War veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14504315" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Occurrence of amyotrophic lateral sclerosis among Gulf War veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15642900" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prospective study of military service and mortality from ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23390184" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23942216" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Early-onset alopecia and amyotrophic lateral sclerosis: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26825926" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Physical Trauma and Amyotrophic Lateral Sclerosis: A Population-Based Study Using Danish National Registries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26783702" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Participation in Physical Activity and Risk for Amyotrophic Lateral Sclerosis Mortality Among Postmenopausal Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27159543" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Association of Environmental Toxins With Amyotrophic Lateral Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27723283" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Increased Incidence of Amyotrophic Lateral Sclerosis in Polymyositis: A Nationwide Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29685899" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Multicentre, cross-cultural, population-based, case-control study of physical activity as risk factor for amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33034341" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Associations of Occupational Exposures to Electric Shocks and Extremely Low-Frequency Magnetic Fields With Motor Neurone Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34910152" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Incidence of and Mortality From Amyotrophic Lateral Sclerosis in National Football League Athletes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28704346" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Mortality from Amyotrophic Lateral Sclerosis and Parkinson's Disease Among Different Occupation Groups - United States, 1985-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33135936" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The human gut microbiota in people with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33468103" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14504310" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Gulf War service is an uncertain trigger for ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24780888" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Dissection of genetic factors associated with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25700176" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22722621" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27455348" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17827064" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27455347" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34135078" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Pathogenic Effect of TP73 Gene Variants in People With Amyotrophic Lateral Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24630593" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : SMN1 duplications contribute to sporadic amyotrophic lateral sclerosis susceptibility: evidence from a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28057713" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25382069" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21562249" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Amyotrophic lateral sclerosis and spinocerebellar ataxia 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33242422" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21047878" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21047878" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13185376" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution, with special reference to the Mariana Islands, including clinical and pathologic observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3603037" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11914415" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18490618" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The ALS/PDC syndrome of Guam and the cycad hypothesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11522574" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Pathological laughter and crying: a link to the cerebellum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6195954" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14517684" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Clinical and pathological studies of familial amyotrophic lateral sclerosis (FALS) with SOD1 H46R mutation in large Japanese families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19204154" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Clinical and pathological continuum of multisystem TDP-43 proteinopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22105541" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22154785" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22094482" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : An autopsy case of SOD1-related ALS with TDP-43 positive inclusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19104447" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Nuclear TAR DNA binding protein 43 expression in spinal cord neurons correlates with the clinical course in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20517935" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31368485" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25932674" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Emerging mechanisms of molecular pathology in ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21956718" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21956724" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : TDP-43 and FUS in ALS/FTLD: will common pathways fit all?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23381726" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : RNA quality control and protein aggregates in amyotrophic lateral sclerosis: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23455423" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22036560" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The seeds of neurodegeneration: prion-like spreading in ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23164372" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Regulated protein aggregation: stress granules and neurodegeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26250685" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35197626" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35197628" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20624952" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24873727" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : C9orf72; abnormal RNA expression is the key.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24598541" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : C9orf72 nucleotide repeat structures initiate molecular cascades of disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26308891" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26315413" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : NEUROSCIENCE. Plugged pores may underlie some ALS, dementia cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25081482" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25103406" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23393093" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24166615" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23720273" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24559645" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25190778" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Cell Biology. Clogging information flow in ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8446170" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16469270" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18268245" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Prevalence of SOD1 mutations in the Italian ALS population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7832899" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Transgenic-mouse model of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8673102" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9178166" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Transgenic animal models of familial amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18219391" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18219386" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Revisiting oxidative damage in ALS: microglia, Nox, and mutant SOD1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18074357" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9143265" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11100110" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Oxidation versus aggregation - how do SOD1 mutants cause ALS?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19416874" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12482932" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16330499" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16291929" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Rapid disease progression correlates with instability of mutant SOD1 in familial ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16380607" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Determinants of rapid disease progression in ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15768029" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24379375" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28564594" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Progressive Motor Neuron Pathology and the Role of Astrocytes in a Human Stem Cell Model of VCP-Related ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28610619" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30711519" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Micro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31841614" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Mutant C9orf72 human iPSC-derived astrocytes cause non-cell autonomous motor neuron pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27688759" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14526083" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17035656" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Amyotrophic lateral sclerosis--are microglia killing motor neurons?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18246065" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23542689" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18492803" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16741123" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Onset and progression in inherited ALS determined by motor neurons and microglia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17373702" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21349440" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18809917" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20348957" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17435755" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22863620" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24607225" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26989253" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : C9orf72 is required for proper macrophage and microglial function in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19672969" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Extracellular mutant SOD1 induces microglial-mediated motoneuron injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20616033" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2375630" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7583686" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9539131" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7611729" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12629173" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15048885" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Altered expression of the glutamate transporter EAAT2b in neurological disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14985749" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Glutamate receptors: RNA editing and death of motor neurons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37641443" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Therapeutic targeting of ALS pathways: Refocusing an incomplete picture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9723164" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Superoxide dismutase and neurofilament transgenic models of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17006927" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Role of neurofilament aggregation in motor neuron disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7536898" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7849698" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9931323" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11089575" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8462101" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11090858" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32385188" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12062019" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12627231" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Mutant dynactin in motor neuron disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15852399" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Distal spinal and bulbar muscular atrophy caused by dynactin mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30643298" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30643292" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9547233" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15233913" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9974149" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16178023" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Mitochondria take center stage in aging and neurodegeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8580727" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Search for persistent infection with poliovirus or other enteroviruses in amyotrophic lateral sclerosis-motor neurone disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15111676" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Failure to detect enterovirus in the spinal cord of ALS patients using a sensitive RT-PCR method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15111658" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : ALS: persistent scientists do not find persisting enteroviruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699374" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18209202" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9511877" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Nervous system Lyme disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11571323" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Reversible ALS-like disorder in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10726972" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : DNA laddering and caspase 3-like activity in the spinal cord of a mouse model of familial amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10331434" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10840278" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Motor neuronal death in sporadic amyotrophic lateral sclerosis (ALS) is not apoptotic. A comparative study of ALS and chronic aluminium chloride neurotoxicity in New Zealand white rabbits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20890041" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10227630" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8967757" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9409357" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9710040" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12847526" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15763997" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15164063" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15568021" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25644224" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23415570" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Controversies and priorities in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32165374" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Family history of neurodegenerative disorders in patients with amyotrophic lateral sclerosis: population-based case-control study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
